Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Raw Materials (2018 - 2025)

Dna X filings provide 8 years of Raw Materials readings, the most recent being $8.1 million for Q3 2025.

  • On a quarterly basis, Raw Materials rose 23.51% to $8.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.1 million, a 23.51% increase, with the full-year FY2024 number at $5.6 million, up 645.41% from a year prior.
  • Raw Materials hit $8.1 million in Q3 2025 for Dna X, up from $6.3 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $8.1 million in Q3 2025 to a low of $3000.0 in Q2 2023.
  • Median Raw Materials over the past 5 years was $2.2 million (2021), compared with a mean of $2.6 million.
  • Biggest five-year swings in Raw Materials: plummeted 99.62% in 2023 and later surged 77900.0% in 2024.
  • Dna X's Raw Materials stood at $2.0 million in 2021, then tumbled by 99.3% to $14000.0 in 2022, then skyrocketed by 5264.29% to $751000.0 in 2023, then soared by 645.41% to $5.6 million in 2024, then surged by 44.34% to $8.1 million in 2025.
  • The last three reported values for Raw Materials were $8.1 million (Q3 2025), $6.3 million (Q2 2025), and $4.3 million (Q1 2025) per Business Quant data.